Early diagnosis and effective therapy are essential for improving the overall prognosis and quality of life of patients with nephropathic cystinosis. The severity of kidney dysfunction and the multi-organ involvement as a consequence of the increased intracellular concentration of cystine highlight the necessity of accurate monitoring of intracellular cystine to guarantee effective treatment of the disease. Cystine depletion is the only available treatment, which should begin immediately after diagnosis, and not discontinued, to significantly slow progression of renal and extra-renal organ damage. This review aims to discuss the importance of the close monitoring of intracellular cystine concentration to optimize cystine depletion therapy. In addition, the role of new biomarkers in the management of the disease, from timely diagnosis to implementing treatment during follow-up, is overviewed.

Biomarkers in Nephropathic Cystinosis: Current and Future Perspectives / F. Emma, G. Montini, M. Pennesi, L. Peruzzi, E. Verrina, B.M. Goffredo, F. Canalini, D. Cassiman, S. Rossi, E. Levtchenko. - In: CELLS. - ISSN 2073-4409. - 11:11(2022 Jun 04), pp. 1839.1-1839.12. [10.3390/cells11111839]

Biomarkers in Nephropathic Cystinosis: Current and Future Perspectives

G. Montini
Secondo
;
2022

Abstract

Early diagnosis and effective therapy are essential for improving the overall prognosis and quality of life of patients with nephropathic cystinosis. The severity of kidney dysfunction and the multi-organ involvement as a consequence of the increased intracellular concentration of cystine highlight the necessity of accurate monitoring of intracellular cystine to guarantee effective treatment of the disease. Cystine depletion is the only available treatment, which should begin immediately after diagnosis, and not discontinued, to significantly slow progression of renal and extra-renal organ damage. This review aims to discuss the importance of the close monitoring of intracellular cystine concentration to optimize cystine depletion therapy. In addition, the role of new biomarkers in the management of the disease, from timely diagnosis to implementing treatment during follow-up, is overviewed.
biomarkers; cysteamine; cystine; kidney; nephropathic cystinosis; therapeutic monitoring
Settore MED/38 - Pediatria Generale e Specialistica
4-giu-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
cells-11-01839.pdf

accesso aperto

Descrizione: Review
Tipologia: Publisher's version/PDF
Dimensione 593.96 kB
Formato Adobe PDF
593.96 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/970044
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact